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Abstract
Drug similarity has been studied to support down-
stream clinical tasks such as inferring novel prop-
erties of drugs (e.g. side effects, indications, in-
teractions) from known properties. The growing
availability of new types of drug features brings
the opportunity of learning a more comprehensive
and accurate drug similarity that represents the full
spectrum of underlying drug relations. However,
it is challenging to integrate these heterogeneous,
noisy, nonlinear-related information to learn accu-
rate similarity measures especially when labels are
scarce. Moreover, there is a trade-off between accu-
racy and interpretability. In this paper, we propose
to learn accurate and interpretable similarity mea-
sures from multiple types of drug features. In par-
ticular, we model the integration using multi-view
graph auto-encoders, and add attentive mechanism
to determine the weights for each view with respect
to corresponding tasks and features for better inter-
pretability. Our model has flexible design for both
semi-supervised and unsupervised settings. Exper-
imental results demonstrated significant predictive
accuracy improvement. Case studies also showed
better model capacity (e.g. embed node features)
and interpretability.
1 Introduction
The rapidly evolving technologies have made it easier to col-
lect multiple types of drug data and thus opened new oppor-
tunities for computational drug discovery research and drug
safety studies. The study of drug similarity paves the founda-
tion for these research since similar structural, molecular and
biological properties often relate to similar drug indications
or adverse effects [Vilar et al., ]. In literature, drug similar-
ity has been computed using molecular structure data [Jin
et al., 2017], interaction profile data [Fokoue et al., 2016],
as well as side-effect information [Cheng and Zhao, 2014;
Liu et al., 2012].
Recently, there has been a growing interest in learning im-
proved drug similarity from multiple types of drug features.
For example, [Li et al., 2015] proposed an inductive ma-
trix completion method to combine multiple data sources and
help predict the unknown side effects. [Zhang et al., 2015]
proposed an integrative label propagation algorithm to infer
clinical side effects from multiple sources with considering
high-order similarity. Results from these pilot studies show
that combined similarity measures are usually more informa-
tive and robust to noise. These methods could be summarized
into four major categories: the nearest neighbor method, the
random walk based approaches, the unsupervised, and the
multiple kernel learning methods. Section 2 provides more
details of the related literature.
Despite potential benefits, when learning from multiple
biomedical data sources, significant challenges arise from the
simultaneous handling of the following issues: 1) different
types of features have different levels of associations with
targeting outcomes. For example, drugs’ structural similarity
could have more influence on their interaction profiles than
drugs’ indication similarity do; 2) the underlying relations
of biomedical events (e.g., two drugs interact to cause a side
effect) are often nonlinear and complex over all types of fea-
tures [Peter et al., 2006]; 3) data quality (e.g. lack of label,
noise in the data) also creates challenges for similarity learn-
ing, and 4) a model that captures complex drug relations is
often be very complex and lacking interpretability.
To address the aforementioned challenges, we consider each
type of drug feature as a view and learn integrated drug sim-
ilarity using multi-view graph autoencoders (GAE). In par-
ticular, we model each drug as a node in the drug associa-
tion network and extend the graph convolutional networks
(GraphCNN) [Kipf and Welling, 2016a] to embed multi-view
node features and edges. Across views, we use attentive view
selection scheme to enable nonlinear multi-view fusion and
make the learning more interpretable and adaptive to data. By
such embedding, we learn drug similarity and use them to
predict outcomes (e.g., drug-drug interactions). In addition,
for the setting where we would like to integrate multiple drug
similarity graph without knowing any features, we propose
an alternative transductive learning method based on treat-
ing labels as latent variables. The proposed models not only
improve prediction performance, but also have the following
benefits.
• Intepretable and adaptive multiview fusion: To model the
heterogeneous relevance among different views with tar-
geting tasks, in our similarity integration, we use attentive
model to fuse multiple views. The attentive view selec-
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tion scheme generates task-wise feature relevance, by
which we could learn interpretable similarity measures.
Also the learned similarity would be more adaptive to the
underlying data, thus is more accurate.
• Transductive prediction using unlabeled data: Labels
are expensive to acquire, and often very scarce for new
drugs. By developing an auto-encoder structure, whose
reconstruction loss could be seen as a regularization term
that explicitly models the information of graph structure,
we efficiently leverage the unlabeled data for accurate
predictions.
• Robust-to-noise: The proposed methods inherit the ad-
vantage of autoencoders and can extract representations
that are relatively stable and robust to the noise in the
data, e.g. in the drug-drug interaction prediction case,
sometimes unseen interactions might not indicate no in-
teraction. The proposed methods effectively reduce the
negative impacts caused by these “positive unlabeled”
samples.
2 Related Work
Our work addresses the problem of multiview similarity
integration. To our best knowledge, current approaches
mainly could be summarized as below.
The nearest neighbor methods that make predictions based
on majority cases among neighbors. To name a few, [Zhang
et al., 2016], [Zhang et al., 2017], and [Zhang et al., 2015].
However, as pointed out by [Zhang et al., 2015], most of these
existing methods only utilize first-order similarity to construct
neighborhood and do not consider transitivity of similarities.
The random walk methods (e.g., label propagation in
[Zhang et al., 2015] and [Wang et al., 2010]) that leverage
the assumption that data points occupying the same manifold
are very likely to share the same semantic label, and then aim
to propagate labeling information from labeled data points to
unlabeled ones according to the intrinsic data manifold struc-
tures collectively revealed by a large number of data points.
These methods can handle nonlinear relations and perform
transductive learning with scarce labeled data. However, these
models have fixed loss functions, hence lack of flexibility in
modeling various problem settings.
The unsupervised methods For example, in [Wang et al.,
2014] and [Angione et al., 2016], the authors construct an
integrative network to fuse multiple similarity networks via an
iterative scaling approach. In [Xu et al., 2016],the authors inte-
grated feature ranking and feature variation as feature weights
for weighted similarity fusion. These unsupervised methods
have good flexibility, however without any supervision, unreli-
able results could be generated.
The multiple kernel learning (MKL) methods such as
[Zhuang et al., 2011]. MKL were further extended to in-
tegrate heterogeneous data in [McFee and Lanckriet, 2011],
however, most existing methods are often limited to convex
integration.
3 Background
Over the past few years, several graph-based convolutional
network models emerged for inducing informative latent fea-
ture representations of nodes and links. For example, [Kipf
and Welling, 2016a] proposed a new graph convolutional net-
work (GraphCNN) that learns node embeddings based on node
features and their connections, which could be used in node
classification. Specifically, given an undirected graph with
nodes X and adjacency matrix A, a multi-layer neural net-
work is constructed on the graph with the following layer-wise
propagation rule:
H(l+1) = f
(
D˜
− 12 A˜D˜
− 12H(l)W (l)
)
where A˜ = A+ IN is the adjacency matrix with added self-
connections, D is a diagonal matrix such that Dii =
∑
j A˜ij ,
W (l) is a layer-specific parameter matrix, H l is the node
representation in the lth layer, and f is an activation function
(e.g. ReLU or sigmoid). Later, [Schlichtkrull et al., 2017] and
[Kipf and Welling, 2016b] extended GraphCNN and proposed
a graph auto-encoder (GAE) using GraphCNN for both node
classification and link prediction tasks. However, their model
only reconstructs the edges, and cannot work on unseen data.
In the following, we will make further extension based on
[Kipf and Welling, 2016b] and [Schlichtkrull et al., 2017] in
terms of reconstructing both links and node embeddings and
allowing for inductive prediction.
4 Method
In this paper, we consider each type of drug feature as a view.
For view u ∈ {1, · · · , T}, we construct a graph by modeling
each drug as a node and the similarity between two nodes as
an edge. We denote node feature embeddings as Z(u) and
use similarity matrixA(u) to represent the pair-wise similarity
between drugs on that view. Given T different views, the task
of multi-view similarity integration is to derive an integrated
node embedding Z and similarity matrixA ∈ Rn∗n across all
views.
4.1 Similarity Integration with Attentive
Multi-view Graph Autoencoders
Basic GraphCNN Structure with Multiple Views For each
view u, we set A˜
(u)
= A(u) + IN and diagonal matrix D(u)
where D(u)ii =
∑
j A˜
(u)
ij , then we use a two-layer GraphCNN
to get the node embeddings Z(u) using Eq. (1).
Z(u) = f(X(u),A(u);W
(u)
1 ) (1)
= Softmax
(
Aˆ
u
ReLU(Aˆ
u
X(u)W
(u)
0 )W
(u)
1
)
,
where Aˆ
u
= D(u)
−1/2
A˜
(u)
D(u)
−1/2
, W (u)0 and W
(u)
1 are
weight matrices. Given the node embeddings Z(u) on each
view u, we concatenate the embedding from each view Z(u)
to get a new representation of the node Z. The prediction
between two nodes xi and xj could be done by a sigmoid
function y(xi, xj) = σ(zTi Wzj) with a matrix parameter
W . The structure of this method is shown in Figure 1(a).
Similarity Matrix Fusion Instead of concatenating node em-
beddings in different views, we can also first get an integrated
similarity matrix and construct only one graph for all views.
In this single graph, the nodes features are fixed for all views.
And the similarity fusion could be simply done as follows:
considering the complexity of normalization, to fuse similarity
we first normalize all similarity matrices Au to get Aˆ
u
, and
then aggregate all similarity matrices to get a comprehensive
one as the adjacency matrix of the graph: Aˆ = 1T
∑
αuAˆ
u
,
where {αu} are mixing weights for different similarity matri-
ces. Following the structure in [Kipf and Welling, 2016a], we
use a one-layer GraphCNN to encode the nodes in our graph:
Z = f(X, Aˆ) = Softmax(AˆXW 0) (2)
After that, we decode the embedding back to the original
feature space
X ′ = f ′(Z, Aˆ) = Sigmoid(AˆZW 1) (3)
If we do not have any labels for the nodes, the objective func-
tion is the loss of the auto-encoder in Eq. 4.
Led =
∑
||X −X ′||2 (4)
In this case, our framework could be regarded as an unsuper-
vised multi-graph fusion and embedding method. The derived
similarity matrix Aˆ can be used for other tasks as well, such
as node clustering.
Attentive View Selection In practice, the fusion of each view
could be nonlinear, while the weights of features in each view
need to be decided by both the data and the targeting tasks.
To allow for such a flexibility, in this section we extend the
mixing scheme by fusing features from different views with at-
tention mechanism, where weights of features are determined
by corresponding inputs. The attentive view selection scheme
is illustrated in Fig. 2.
Assume we have adjacency matrixAu for view u, we assign
attention weights gu ∈ RN∗N to the graph edges, such that
the integrated adjacency matrix becomes
∑
u g
uAu, where
 is the element wise multiplication. For each view, we
first project the original adjacency matrix to an unnormalized
matrix g′u = W uAu + bu, and then normalize them over
different views to get the attention weights gu. In practice, the
graph is often large, thus there will be too many parameters
for the attention calculation if we use a fully connected N ∗N
attention matrix. To reduce the complexity, we alternatively
employ a diagonal attention matrix. To be specific, we limit
gu to be a vector, and form the weighted similarity matrix
by diag(gu) ∗ Au. In this way, the size of parameters (i.e.
W u and bu ) is reduced from N ∗N to N . And the attentive
similarity matrix is generated as follows: g′u =W uAu+ bu,
where W u, bu ∈ R1∗N .
Then we normalize them to get the attention weights for
each position i: gi = (g1i , ..., g
T
i ) = Softmax(g
′1
i , ..., g
′T
i ),
and gu = (gu1 , ...g
u
N ) is then used to induce the final simi-
larity matrix A =
∑
u diag(g
u) ∗Au, where ∗ is the matrix
multiplication, diag(gu) is a diagonal matrix of gu as its di-
agonal value. After we get the new attention based similarity
matrix A, we can use the same framework as 4.2 and 4.3.
4.2 A Semi-supervised Extension Given Partial
Labeled Data
The graph auto-encoder (GAE) structure could be further
extended to a semi-supervised setting when we have labels
for some of the nodes in the graph (in our case drugs). We
could keep the auto-encoder framework unchanged, and pre-
dict the labels on training data using a network h: h(Z) =
Softmax(W hZ + bh). The prediction loss of h is formulated
by Eq. (5).
Ltrain = L(Ytrain, h(Z train)) =
∑
y∈Y train
∑
y′∈h(Z train)
−y ln y′ (5)
This new model then integrates the two loss functions as its
objective function
L = Ltrain + λLed (6)
Compared to a generic neural network, which generally
contains only the Ltrain, Eq. (6) can be seen as adding
an auto-encoder loss as the regularization term Led. In a
graph based semi-supervised learning framework, the graph
Laplacian regularization is often used as the regularization
to capture the graph structure. L = Ltrain + λLlap, where
Llap =
∑
i,jAi,j ||h(xi)− h(xj)||2. Our objective function
replaces the second term with the reconstruction loss of the
GAE, which also explicitly models the graph structure infor-
mation.
4.3 Transductive Learning using Test Labels as
Variables
Sometimes when we only have the graph structure of the simi-
larity matrix but no node features, although we could model
them using one-hot representation as in [Kipf and Welling,
2016a] (for details, see Appendix A.1 in [Kipf and Welling,
2016a]), such embedding is typically not efficient. More im-
portantly decoding the embedding vectors to the one-hot vec-
tors cannot gain much information. This motivates us to de-
velop another scheme to extend the previous introduced graph
auto-encoder to improve learning given no node feature.
Instead of using the original node features or one-hot node
vectors in GAE, we consider an alternative way: we use the
training labels (i.e. DDI links of each node) as inputs and re-
construct them using the same GAE structure as in Figure 1(c).
So the graph auto-encoder would output the predicted links
Y ′ = f ′(f(Y , Aˆ), Aˆ).
Moreover, if we consider similarities as graph edges, the
labels of the test nodes would also impact the decoding of the
training nodes. So we employ a transductive method to use the
test labels as additional latent variables. The predicted labels
are formulated as follows:
{Y ′train,Y ′test} = f ′(f({Y train,Y test}, Aˆ), Aˆ) (7)
i.e. Y ′test is a function of Y test when Y
′
train, Y train and Aˆ are
known. The objective function of this model is then given by:
min
Ytest
L = ||Y ′train − Y train||2 + ||Y ′test − Y test||2 + µ||Y test||2,
(a) (b) (c)
Figure 1: The illustration of GraphCNN for link prediction: (a) The basic GraphCNN structure with multiple similarity matrices. (b)
Semi-supervised graph auto-encoder based on GraphCNN. (c) Transductive graph auto-encoder.
Figure 2: The illustration of attention view selection scheme.
where µ||Y test||2 is a regularization term which enforces sta-
bility of the solutions. Thus after inference from the training
data, we can get the optimal neural network parameters as
well as the latent variables Ytest.
5 Experiment
Detecting adverse drug-drug interaction (DDI), a modifica-
tion of the effect of a drug when administered with another
drug, is one of the clinically important applications as DDIs
result in large amounts of fatalities per year and incur huge
morbidity and mortality related cost of ∼ $177 billion annu-
ally [Giacomini et al., 2007]. Making use of multiple drug
characterizations in similarity computation is critical since
drugs could have heterogeneous similarity in different feature
dimensions, e.g. drugs that have similar chemical structures
could have very different therapeutic target and thus result in
different DDI mechanism.
5.1 Data Sources
Binary Prediction of the Occurrence of DDIs: For the
first data set, we will integrate multiple similarity graph
(without node feature) to predict whether there will be
interaction between a new pair of drugs. In the data, we have
the following views: 1) DDI: The known labels of DDIs
are extracted from the Twosides database [Tatonetti et al.,
2012], including 645 drugs and 1318 DDI events, in total
63473 distinct pairs of drugs associated with DDI reports.
2) Label Side Effect: Drugs’ side effects extracted from
SIDER database [Kuhn et al., 2015] are considered one
type of features, including 996 drugs and 4192 side effects.
We call this view as “Label Side Effect” by the convention
in [Zhang et al., 2015]. 3) Off-Label Side Effect: Drugs
confounder-controlled side effects from OFFSIDES dataset
are considered another type of features, including 1, 332
drugs and 10, 093 side effects. 4) Chemical Structure: Drug
structure features (i.e. chemical fingerprints) are structural
descriptors of drugs. In our study, we generate drug structure
features with the extended-connectivity fingerprints with
diameter 6 (ECFP6) using the R package “rcdk [Guha, 2007]”.
The features are hashed binary vectors of 1,024-bit length,
of which each bit encodes the presence or absence of a
substructure in a drug molecule. We used Jaccard index to
compute similarities between all the fingerprints.
Multilabel Prediction of Specific DDI Types: For the sec-
ond data, we integrate multiple type of drug views to predict
specific interaction types among 1301 candidate types for new
drug pairs. In the data, we have 222 drugs and the following
views: 1) Drug Indication: The drug indication data of dimen-
sion 1702 is downloaded from SIDER [Kuhn et al., 2015]. It
is originally generated from MedDRA database, which is a
widely used clinically-validated international medical termi-
nology. 2) Drug chemical protein interactome (CPI): The CPI
data from [rep, 2016] provides an important measure about
how much power a drug needs to bind with its protein target.
Its dimension is 611. The similarity of CPI is calculated using
the RBF kernel. 3) Protein and nucleic acid targets (TTD):
For each drug, we associate its multiple protein and nucleic
acid targets information and generate features of dimension
207. These entries are extracted from the Therapeutic Target
Database (TTD) [Chen et al., 2002]. 4) Chemical Structure:
The chemical structure features are extracted in the same way
as in dataset 1, except that we chose “pubchem” fingerprint
instead, whose feature dimension is 582.
5.2 Implementation and Evaluation Strategy
Proposed Model: We implement the proposed model with
Tensorflow 1.0 [Abadi et al., 2015] and trained using Adam
with learning rate 0.01 and early stopping with window
size 30. We optimized the hyperparameter for SemiGAE
on validation data and then fixed for all GAE models: 0.5
(dropout rate), 5e-4 (L2 regularization) and 64 (# of hidden
units). For GCN models, we have the second layer and the
number of the hidden units in the second layer is set as 32.
Baseline: In addition, we implemented the following four
baselines for comparison:
• Nearest Neighbor (NN): We implemented the NN method
in [Vilar et al., 2012]. It identifies novel DDIs by us-
ing the nearest neighbor similarity to drugs involved in
established DDIs.
• Label Propagation (LP): We considered the LP model
in [Zhang et al., 2015] as a baseline. The LP method
propagates the existing DDI information in the network
to predict new DDIs, and could also integrate multiple
similarity matrices in the network.
• GraphCNN: For single view, we use the same structure
as the nonprobabilistic GAE model in [Kipf and Welling,
2016b]. We consider the DDI links as edges and form
the adjacency matrix. For multiple views, we linearly
integrate all similarity matrices as well as the training
DDI links.
• Multiple Kernel Learning (MKL): For MKL, we used the
python “Mklaren” library [Strazar and Curk, 2016]. We
set σ = 30 for RBF and degree p = 3 for polynomial
kernel. We only applied MKL on Data 2 since Data 1
does not have features for all views.
For all models, we use Tanimoto coefficient (TC) to calculate
similarity except for CPI. For CPI, we measure drug similarity
using RBF kernel. For all methods (except NN which already
has the similar procedure in its method), following the
procedures in [Zhang et al., 2016], after getting the predicted
labels using our model, we calculate the probability of that
drug i interacts with drug j by scoreji = scoreij = Yij+Yji.
Evaluation: In evaluation, we adopted strategies in [Zhang
et al., 2015] and randomly selected a fixed percentage (i.e.,
25% and 50%) of drugs, and moved all DDIs associated with
these drugs for testing. For the data not in testing, we train on
90% and perform validation and model selection on 10% of
the drugs. For testing data, we repeated the hold-out validation
experiment 50 times with different random divisions of the
data, and reported the mean and the standard deviation of the
area under the receiver operating characteristic curve (ROC-
AUC) as well as the area under the precision-recall curve (PR-
AUC) over the 50 repetitions. In the ROC and PR analytics,
we utilized DDI interactions from TWOSIDES as reference
positives, and the complement set as reference negatives.
5.3 Results
Table 1 and 2 compare the performance of the proposed
models against baselines on both datasets. From the tables
we can see for both single view and multi-view, the proposed
models significantly outperform baselines. Also, the multi-
view models generally outperform corresponding single view
models since our integrations provide more comprehensive
measures of drug similarity. With adding attention mecha-
nism, the relevant types of features receive more weights in
similarity integration.
In addition, we observed that the attentive semi-supervised
GAE (AttSemiGAE, the model of Section 4.2) often achieves
the best ROC-AUC, which is due to the embedding of node
features. This advantage is more obvious on Dataset 2 than
Dataset 1, since for Dataset 2, we have node features on all
views, while most views in Dataset 1 have no node feature. For
Dataset 1, due to the lack of node feature in most views, the
attentive transductive GAE (attTransGAE, the model of Sec-
tion 4.3) gains better PR-AUC thanks to transductive learning
from tests labels and adaptive weight learning.
5.4 Case Studies
Understanding the Major Source of Similarity When two
drugs cause similar DDIs, such a similarity could be induced
by various mechanisms. For example, drugs that prolong the
QT interval, drugs that are CYP3A4 inhibitors, or drugs that
alter another drug’s metabolism via cytochrome P450 interac-
tions or changes in protein binding, etc [Ansari, 2010]. Better
understanding the major DDI mechanism would benefit us
from developing actionable insights to identify proper ways to
prevent DDIs. In this paper, adding attention mechanism en-
hances the interpretability of the models and could potentially
provide understanding of the underlying DDI mechanism.
Table. 3 reports several selected DDIs and the weights of
each views as predicted using AttSemiGAE. For example,
the DDI “chest pain” has good prediction AUC, and the
views “CPI” and “indication” both have more impact on the
predictions than other views. We consult domain expert, and
find it in line with domain knowledge. Many DDI cases
of chest pain are due to particular drug overdose, such as
Venlafaxine and Mirtazapine [Nachimuthu et al., 2012],
which could be prescribed together to treat depression.
However, the co-use of them could cause overdose thus
prolong the QT interval via chemical protein interactome
(CPI), and eventually cause chest pain. For another DDI
“insomnia”, one major mechanism is the interaction between
cytochrome P450 (CYP) inducers (e.g. Rifampicin) and
Hypnosedatives. Insomnia happens when the cytochrome
P450 (CYP) inducers significantly induce the metabolism
of the newer hypnosedatives and decreased their sedative
effects [Hesse et al., 2003]. Such a process was caused by the
bindings of chemical structures with proteins. In the results,
the weights for “pubchem” and “CPI (compound-protein bind-
ing)” are much higher than the rest, in line with knowledge.
Importance of Multiview Feature Integration: We also ex-
amined how feature integrations across multiples views of
features could help provide more accurate measures of drug
similarity.
For example, Acyclovir (Pubchem ID 2022) and Ganci-
clovir (Pubchem ID 3454), having medium level similarity
in indication and TTDS, since Acyclovir is used for treat-
ing herpes simplex virus infections and shingles but Ganci-
clovir is mainly used in more severe Cytomegalovirus dis-
eases and AIDS. However, they both are analogues of 2’-
deoxyguanosine and have very high structural similarity (0.961
measured using “Pubchem” fingerprint). The high structural
similarity lead to many common DDIs shared by the two drugs
according to the groundtruth. Our proposed model adaptively
gives more weight to the structural similarity and computes
Table 1: Predicting Binary DDI Outcomes on Dataset 1.
Using Single View
Methods
Test Split (25%) Test Split (50%)
ROC-AUC PR-AUC ROC-AUC PR-AUC
Baselines
NN 0.693± 0.025 0.504± 0.043 0.681± 0.027 0.498± 0.042
LP 0.769± 0.013 0.648± 0.028 0.752± 0.018 0.632± 0.035
GraphCNN 0.723± 0.028 0.536± 0.050 0.717± 0.039 0.528± 0.076
Proposed
SemiGAE 0.788± 0.014 0.640± 0.036 0.785± 0.012 0.637± 0.035
TransGAE 0.786± 0.013 0.644± 0.033 0.776± 0.013 0.630± 0.039
Using Multiple Views
Baselines
LP 0.768± 0.013 0.644± 0.028 0.751± 0.018 0.629± 0.036
GraphCNN 0.696± 0.061 0.515± 0.066 0.636± 0.047 0.457± 0.064
Proposed AttSemiGAE 0.798± 0.013 0.655± 0.032 0.791± 0.017 0.642± 0.037
AttTransGAE 0.785± 0.012 0.687± 0.023 0.780± 0.016 0.678± 0.031
Table 2: Predicting Specific DDI Types (Multiple Outcomes) on Dataset 2.
Using Single View
Methods
Test Split (25%) Test Split (50%)
ROC-AUC PR-AUC ROC-AUC PR-AUC
Baselines
NN 0.627± 0.043 0.594± 0.078 0.594± 0.033 0.554± 0.061
LP 0.773± 0.025 0.670± 0.052 0.747± 0.028 0.650± 0.053
GraphCNN 0.738± 0.047 0.594± 0.080 0.698± 0.090 0.583± 0.102
Proposed
SemiGAE 0.798± 0.029 0.661± 0.059 0.784± 0.028 0.649± 0.059
TransGAE 0.790± 0.028 0.661± 0.068 0.770± 0.031 0.633± 0.080
Using Multiple Views
Baselines
LP 0.774± 0.025 0.672± 0.052 0.748± 0.028 0.653± 0.055
GraphCNN 0.601± 0.067 0.526± 0.120 0.578± 0.067 0.526± 0.108
MKL 0.766± 0.030 0.650± 0.061 0.724± 0.026 0.586± 0.066
Proposed AttSemiGAE 0.802± 0.029 0.678± 0.060 0.786± 0.030 0.662± 0.064
AttTransGAE 0.782± 0.026 0.670± 0.058 0.764± 0.025 0.652± 0.061
Table 3: Attention Weights for Selected DDIs
DDI Type AUC chem. indi. TTDS CPI
Chest Pain 0.772 0.151 0.303 0.144 0.402
Insomnia 0.755 0.380 0.261 0.078 0.291
Aching Muscles 0.774 0.117 0.301 0.283 0.299
an integrated similarity score at 0.682, but label propagation
(LP) fails to capture such heterogeneous influences and yields
an integrated score at only 0.551, which is an underestimate
comparing with the groundtruth.
Similar examples include the similarity between Alprazo-
lam (Pubchem ID 2118) and Estazolam (Pubchem ID 3261)
as well as the similarity between Alprazolam (Pubchem ID
2118) and Triazolam (Pubchem ID 5556). The two pairs of
drugs have quite low indication similarity, however, they all
interact when in combined use with CYP3A4 inhibitors such
as Cimetidine, Erythromycin, Norfluoxetine, Fluvoxamine,
Itraconazole, Ketoconazole, Nefazodone, Propoxyphene, and
Ritonavir. The combined uses will delay the hepatic clearance
of Alprazolam, Estazolam or Triazolam, which then cause
accumulation and increased severity of side effects from these
drugs. The proposed model account for the feature heterogene-
ity and weight more on the chemical structural feature and
CPI feature, leading to integrated similarity at 0.682 ∼ 0.720,
while other methods considered each views homogeneously
and the resulting similarity is often low at 0.551 ∼ 0.630.
6 Conclusion
In this paper, we proposed a set of Graph Auto-Encoder based
models that perform multi-view drug similarity integration
with attention model to perform view selection. The nonlin-
ear and adaptive integration not only offers superior predic-
tive performance but also interpretable results. We extended
these GAE models to semi-supervised/transductive settings
and predict the unknown DDIs. Experimental results on two
real-world drug datasets demonstrated the performance and ef-
ficacy of our methods. Future works include expansion along
the line of data or model. Data-wise, we could try on a larger
drug database to fully exploit of the power of deep learning
without overfitting. Model-wise, we will pursuit directly com-
puting integrated similarity across multiple views without the
need for calculation similarity for each view first.
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